Christina Loguidice


New Treatment Options Are in Play for Relapsed/ Refractory DLBCL

May 12th 2022

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

A New Era of Precision Medicine Takes Shape in Prostate Cancer

October 26th 2021

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Sequencing Therapy in Metastatic CRC Is a Marathon, Not a Sprint

June 24th 2021

Actionable mutations identified in colorectal cancer have contributed significantly to the expansion of the therapeutic options available for patients with metastatic disease.

Investigators Set Sights on Curative Approaches for Follicular Lymphoma

June 15th 2021

The majority of patients with indolent follicular lymphoma do well with observation and after first-line treatment, but approximately 20% experience disease progression within 2 years of their initial treatment, which is associated with a 50% risk of dying within 5 years. Subsequently, this is an area of unmet need but one in which considerable progress is being made.

Finding the Golden Ticket in Cholangiocarcinoma: Entering the Era of Precision Medicine

May 6th 2021

The highly heterogeneous nature of cholangiocarcinoma at the genomic, epigenetic, and molecular levels has led to the development of effective new treatments for patients with these rare malignant tumors.

Landscape for Unresectable HCC Comes Into Sharper Focus

April 27th 2021

After years of stagnation, the paradigm for treating patients with unresectable intermediate-stage or advanced hepatocellular carcinoma is starting to change as a result of novel strategies and evolving views of appropriate patient populations for systemic therapies.

Frontline Treatment Arsenal Expands in Advanced HCC

January 11th 2021

Although rates of hepatocellular carcinoma incidence started to plateau in 2013, many cases continue to be diagnosed at more advanced stages, especially in patients without liver disease.

4 Biomarker-Driven Regimens Propel Frontline Advances in Ovarian Cancer

November 28th 2020

Targeted therapy approaches have expanded rapidly in ovarian cancer over the past 3 years, with the FDA approving 4 new strategies in frontline settings that allow women to remain free of disease progression longer than the previous standard of care.

Panelists Stress Importance of Putting Your Best Foot Forward in Advanced RCC

October 23rd 2020

Kidney cancer experts emphasize the importance of risk stratification for guiding treatment decisions and discussed the clinical trials that have shaped the frontline treatment recommendations from the National Comprehensive Cancer Network for advanced clear cell RCC.

The Rising Incidence of Early-Onset CRC: What Do We Know and What Can We Do?

July 24th 2018

During an OncLive Peer Exchange® program on individualizing treatment and improving outcomes for patients with CRC, a panel of experts shared their insights on early-onset CRC, which has been observed to occur as early as adolescence.

Excitement Grows About PARP Inhibitors in BRCA-Mutated TNBC

April 4th 2018

A panel of experts discusses the role of BRCA1/2 mutation testing and how and when to incorporate PARP inhibitors into the care of patients with BRCA-positive TNBC.

Bright Future for Gene Therapy in Hematologic Malignancies

February 28th 2018

A panel of experts discusses the current state of CAR T-cell therapies and sheds light on the future directions of this therapeutic approach.

Experts Discuss Strategies for Boosting Frontline Responses in Myeloma

September 4th 2017

During the past decade, the treatment of multiple myeloma has significantly changed, enabling more patients to achieve deep and durable responses.

Testing Picture Is Coming Into Sharper Focus for Familial and Hereditary Prostate Cancer

August 16th 2017

Research into the biology of prostate cancer has resulted in a growing understanding of the molecular drivers of the malignancy, resulting in a rapid evolution of genetic testing that is poised to revolutionize the diagnosis and care of at-risk men as well as those who have the disease.

Complex Scenarios in Advanced Melanoma: Examining Three Patient Cases

February 8th 2017

Despite significant developments on the advanced melanoma treatment front, “many clinical scenarios remain where there is no clear-cut course of action," said Robert H.I. Andtbacka, MD, CM, during a recent OncLive Peer Exchange®.

Challenges Persist in Deploying ADT in Prostate Cancer

January 11th 2017

In 1941, Charles Brenton Huggins, MD, observed that prostate cancer could be controlled by hormone-directed treatments, a discovery for which he was awarded half the Nobel Prize in Physiology or Medicine in 1966.

From Hospice to Remission: Hopes Remain High for CAR Therapies

October 28th 2016

Patients with advanced lymphoid malignancies have had few treatment options, particularly those with extensive, refractory disease. Allogeneic or autologous hematopoietic stem cell transplantation has been one life-prolonging and potentially curative option for these patients, but these procedures are associated with various toxicities and are not appropriate for all patients, with older adults and those with great- er disease burden often excluded as candidates.

Leading Researchers Dissect PD-1/PD-L1 Evidence in NSCLC

September 15th 2016

Although lung cancer remains the leading cause of cancer-related mortality in the United States and 5-year survival rates are low at 17.8%, the grim picture for this tumor type is starting to shift to a more hopeful one as its biology is becoming better understood, facilitating treatment selection and providing researchers with new therapeutic targets.

CRC Biomarkers Exert Growing Influence on Prognosis and Treatment

September 2nd 2016

Molecular testing for colorectal cancer continues to evolve at a rapid pace. Biomarkers already have the potential to predict outcomes and better target therapies, with the eventual goal to completely personalize treatments based on the patient’s individual biomarker profile and other tumor markers.

Highlights from the NCCN 
15th Annual Conference

June 3rd 2010

The National Comprehensive Cancer Network (NCCN) recently held its 15th Annual Conference in Hollywood, Florida. The conference was entitled �Clinical Practice Guidelines & Quality Cancer Care� and included multiple presentations with updates to the NCCN Guidelines. We cover updates to the NCCN Guidelines for breast cancer, acute myeloid leukemia, and multiple myeloma.